MetaCap

Johnson & Johnson (JNJ) vs Vertex Pharmaceuticals (VRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Johnson & Johnson (JNJ) has outperformed Vertex Pharmaceuticals (VRTX) over the past year, gaining 32.6% versus a gain of 20.7%. Over five years, VRTX leads with a +180.5% price change compared with +69.9% for JNJ. Johnson & Johnson is the larger company by market cap ($651.11 billion vs $130.58 billion), about 5.0 times the size, while Vertex Pharmaceuticals is growing revenue faster (+8.9% vs +6.0%).

On valuation, Johnson & Johnson trades at a lower forward P/E (23.3x vs 25.9x for Vertex Pharmaceuticals). Johnson & Johnson pays a dividend yielding 1.95%, while Vertex Pharmaceuticals does not currently pay one. Vertex Pharmaceuticals converts more of its revenue into profit, with a net margin of 32.9% versus 28.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JNJ+32.65%VRTX+20.68%
+42%+19%-4%
Nov 21, 20251 yearNov 20, 2026
JNJ+66.04%VRTX+181.62%
+217%+96%-24%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JNJ versus VRTX key metrics
MetricJNJVRTX
Share price$270.47$515.02
Market cap$651.11B$130.58B
1-day change+1.25%-1.08%
YTD return+30.69%+13.60%
1-year return+32.65%+20.68%
5-year return+69.89%+180.53%
P/E ratio (TTM)41.0433.14
Forward P/E23.2925.86
EPS (TTM)$6.59$15.54
Dividend yield1.95%0.00%
Annual dividend$5.28$0.00
Revenue (latest FY)$94.19B$12.00B
Revenue growth (YoY)+6.05%+8.90%
Net income (latest FY)$26.80B$3.95B
Gross margin67.88%86.24%
Operating margin—34.77%
Net margin28.46%32.94%
52-week high$290.25$568.67
52-week low$199.91$412.27
Distance from 52-week high-6.81%-9.43%
Analyst consensusbuybuy
Avg. price target upside+3.31%+15.60%
Average volume7.29M1.25M
Shares outstanding2.41B253.54M
Employees138,2006,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Johnson & Johnson is about 5.0 times larger than Vertex Pharmaceuticals by market value ($651.11B vs $130.58B).
  • JNJ has outperformed VRTX by 12.0 percentage points over the past year.
  • Johnson & Johnson offers a meaningfully higher dividend yield (1.95% vs 0.00%).

About Johnson & Johnson

JNJ stock →

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.

Health Care · Biotechnology: Pharmaceutical Preparations · 138,200 employees

About Vertex Pharmaceuticals

VRTX stock →

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees

JNJ vs VRTX FAQ

Which is bigger, Johnson & Johnson or Vertex Pharmaceuticals?

Johnson & Johnson (JNJ) is larger, with a market capitalization of $651.11B compared with $130.58B for Vertex Pharmaceuticals (VRTX).

Which stock has performed better over the past year, JNJ or VRTX?

JNJ returned +32.65% over the past 12 months, compared with +20.68% for VRTX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, JNJ or VRTX?

VRTX has the lower trailing P/E at 33.1, versus 41.0 for JNJ. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Johnson & Johnson or Vertex Pharmaceuticals?

Johnson & Johnson pays a dividend yielding 1.95%, while Vertex Pharmaceuticals does not currently pay a regular dividend.

Are Johnson & Johnson and Vertex Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons